Exhibit 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13D, dated January 28, 2021, with respect to the ordinary shares of Prevail Therapeutics Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 28^th day of January 2021.

	ORBIMED ADVISORS LLC


	By:	/s/ Jonathan Silverstein
		Name: Jonathan Silverstein
		Title: Member

	ORBIMED CAPITAL GP VI LLC

	By:	ORBIMED ADVISORS LLC, its managing member

	By:	/s/ Jonathan Silverstein
		Name: Jonathan Silverstein
		Title: Member of OrbiMed Advisors LLC

Prevail Therapeutics Inc. SC 13D/A